相关实验视频

Updated: Sep 17, 2025

Characterization at the Molecular Level using Robust Biochemical Approaches of a New Kinase Protein

Characterization at the Molecular Level using Robust Biochemical Approaches of a New Kinase Protein

Published on: June 30, 2019

共价向导致开发一个LIMK1同型选择性抑制剂

Sebastian Mandel^1,2, Thomas Hanke^1,2, Niall Prendiville³

¹Institute for Pharmaceutical Chemistry, Johann Wolfgang Goethe-University, Max-von-Laue-Str. 9, D-60438 Frankfurt am Main, Germany.

Journal of medicinal chemistry

|July 2, 2025

概括

研究人员通过向独特的氨酸残留物开发了一种对LIMK1,一种蛋白质激酶的选择性共价抑制剂. 这种化学探测器可以对LIMK1进行精确的研究.

科学领域:

生物化学生物化学
化学生物学化学生物学
分子药理学分子药理学

背景情况:

实现蛋白质激酶的异形选择性对于药物设计和化学探针开发至关重要.
对独特的氨酸残留物的共价向提供了一种克服保护结合点挑战的策略.
LIMK (LIM激酶) 家族,特别是LIMK1和LIMK2,在细胞过程中起着至关重要的作用.

研究的目的:

为LIMK1.1设计和表征一种细胞活性,异形选择性共价抑制剂.
利用LIMK1-特定的氨酸向来提高对LIMK2的选择性.
为研究LIMK1信号通路提供一个多功能化学工具.

主要方法:

利用泛LIMK抑制剂支架开发了一个LIMK1-选择性共价抑制剂.
准位于富含甘氨酸的循环中的LIMK1特异性氨酸C349.
研究了非共价和共价LIMK抑制剂的结合动力学.
在抑制剂设计中采用了I型抑制剂的特性 (快速启动率,小尺寸).
使用拉下测试验证了全蛋白质组的选择性.

主要成果:

开发了一种细胞活性共价抑制剂,可以选择性地针对LIMK1而不是LIMK2.
证明了开发的抑制剂的优异的蛋白质组范围选择性.
确认了LIMK1特异性氨酸C349.9的向.
抑制剂的设计结合了快速启动率和小尺寸的特征.

结论:

成功开发了一种新型,高度选择性的共价性LIMK1抑制剂.
这种抑制剂作为一种有价值的化学探针,用于研究LIMK1异形特异性功能.
向独特的囊蛋白的方法是有效的,以实现激酶选择性.
该工具有助于对LIMK信号通路的研究.

更多相关视频

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays

Published on: June 13, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...